Illumina to Announce Fourth Quarter and Fiscal Year 2012 Financial Results on Monday, January 28, 2013

  Illumina to Announce Fourth Quarter and Fiscal Year 2012 Financial Results
  on Monday, January 28, 2013

Business Wire

SAN DIEGO -- January 15, 2013

Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for
fourth quarter and fiscal year 2012 following the close of market on Monday,
January 28, 2013.

On the same day, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) Jay
Flatley, President and Chief Executive Officer; Marc Stapley, Senior Vice
President and Chief Financial Officer; and Christian Henry, Senior Vice
President and General Manager, Genomic Solutions will host a conference call
with analysts, investors, and other interested parties to discuss financial
and operating results.

Conference Call Details

The conference call will begin at 2:00 p.m. Pacific Time (5:00 p.m. Eastern
Time) on Monday, January 28, 2013. Interested parties may listen to the call
by dialing 888-679-8035 (passcode: 35493315), or if outside North America, by
dialing +1-617-213-4848 (passcode: 35493315). Individuals may access the live
teleconference in the Investor Relations section of Illumina's web site under
the “Company” tab at www.illumina.com.

A replay of the conference call will be available from 4:00 p.m. Pacific Time
(7:00 p.m. Eastern Time) on January 28, 2013 through February 4, 2013 by
dialing 888-286-8010 (passcode: 76555573), or if outside North America, by
dialing +1-617-801-6888 (passcode: 76555573).

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA and protein.
We also provide tools and services that are fueling advances in consumer
genomics and diagnostics. Our technology and products accelerate genetic
analysis research and its application, paving the way for molecular medicine
and ultimately transforming healthcare.

Contact:

Illumina, Inc.
Investors:
Rebecca Chambers, 858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple, 858-882-6822
pr@illumina.com
 
Press spacebar to pause and continue. Press esc to stop.